文献速递血栓与止血

口服Xa因子抑制剂与低分子量肝素在合并静脉血栓栓塞的癌症患者中的比较:随机试验(SELECT-D)结果

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
PubMed 文献 · J Clin Oncol · 2018-05-10

SELECT-D是一项在英国开展的多中心、随机、开放标签、先导性试验,比较达肝素与利伐沙班治疗活动性癌症合并症状性肺栓塞、偶发肺栓塞或症状性下肢近端深静脉血栓患者。6个月静脉血栓栓塞复发率利伐沙班组4%低于达肝素组11%(HR 0.43),但临床相关非大出血利伐沙班组13%高于达肝素组4%(HR 3.76),大出血两组无显著差异。

要点

  • 6个月静脉血栓栓塞复发率利伐沙班组4% vs 达肝素组11%(HR 0.43,95%CI 0.19–0.99)。
  • 6个月临床相关非大出血率利伐沙班组13% vs 达肝素组4%(HR 3.76,95%CI 1.63–8.69)。
  • 6个月大出血率利伐沙班组6% vs 达肝素组4%(HR 1.83,95%CI 0.68–4.96),未达统计学显著。

核心结论

  • 与达肝素相比,利伐沙班与相对较低的静脉血栓栓塞复发率相关,但临床相关非大出血发生率更高。

研究设计与样本

  • 英国多中心、随机、开放标签、先导性试验,纳入活动性癌症合并症状性肺栓塞、偶发肺栓塞或症状性下肢近端深静脉血栓患者。
  • 患者随机分配至达肝素组(第1个月每日200 IU/kg,第2–6个月每日150 IU/kg)或利伐沙班组(15 mg每日两次共3周,之后20 mg每日一次,总疗程6个月)。
  • 每组各203例患者,58%有转移。
  • 主要结局为6个月静脉血栓栓塞复发;安全性通过大出血和临床相关非大出血评估。
  • 假设6个月静脉血栓栓塞复发率为10%,400例样本量可提供±4.5%以内的复发率估计。

主要发现

  • 26例患者发生静脉血栓栓塞复发(达肝素组n=18,利伐沙班组n=8)。
  • 6个月累积静脉血栓栓塞复发率达肝素组11%(95%CI 7%–16%)vs 利伐沙班组4%(95%CI 2%–9%)(HR 0.43;95%CI 0.19–0.99)。
  • 6个月累积大出血率达肝素组4%(95%CI 2%–8%)vs 利伐沙班组6%(95%CI 3%–11%)(HR 1.83;95%CI 0.68–4.96)。
  • 6个月累积临床相关非大出血率达肝素组4%(95%CI 2%–9%)vs 利伐沙班组13%(95%CI 9%–19%)(HR 3.76;95%CI 1.63–8.69)。

关键数值与推荐

  • 达肝素给药方案:第1个月每日200 IU/kg,第2–6个月每日150 IU/kg。
  • 利伐沙班给药方案:15 mg每日两次共3周,之后20 mg每日一次,总疗程6个月。
  • 主要结局为6个月静脉血栓栓塞复发;安全性指标为大出血和临床相关非大出血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ± 4.5%, assuming a VTE recurrence rate at 6 months of 10%. Results A total of 203 patients were randomly assigned to each group, 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (dalteparin, n = 18; rivaroxaban, n = 8). The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99). The 6-month cumulative rate of major bleeding was 4% (95% CI, 2% to 8%) for dalteparin and 6% (95% CI, 3% to 11%) for rivaroxaban (HR, 1.83; 95% CI, 0.68 to 4.96). Corresponding rates of CRNMB were 4% (95% CI, 2% to 9%) and 13% (95% CI, 9% to 19%), respectively (HR, 3.76; 95% CI, 1.63 to 8.69). Conclusion Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018. PMID: 29746227. doi:10.1200/JCO.2018.78.8034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。